Effect of the Combined Use of Tramadol and Milnacipran on Pain Threshold in an Animal Model of Fibromyalgia

Seong-Ho Kim, Junhwa Song, Hyunil Mun and Keon Uk Park

Department of Internal Medicine, Dongguk University College of Medicine, Gyeongju, Korea

Background/Aims: Acidic saline injections produce mechanical hyperresponsiveness in male Sprague-Dawley rats. We investigated the effect of milnacipran in conjunction with tramadol on the pain threshold in an acidic saline animal model of pain.

Methods: The left gastrocnemius muscle of 20 male rats was injected with 100 µL of saline at pH 4.0 under brief isoflurane anesthesia on days 0 and 5. Rats administered acidic saline injections were separated into four study subgroups. After determining the pre-drug pain threshold, rats were injected intraperitoneally with one of the following regimens; saline, milnacipran alone (60 mg/kg), milnacipran (40 mg/kg) plus tramadol (20 mg/kg), or milnacipran (40 mg/kg) plus tramadol (40 mg/kg). Paw withdrawal in response to pressure was measured at 30 min, 120 min, and 5 days after injection. Nociceptive thresholds, expressed in grams, were measured with a Dynamic Plantar Aesthesiometer (Ugo Basile, Italy) by applying increasing pressure to the right or left hind paw until the rat withdrew the paw.

Results: A potent antihyperalgesic effect was observed when tramadol and milnacipran were used in combination (injected paw, \( p=0.001 \); contralateral paw, \( p=0.012 \)). This finding was observed only at 30 min after the combination treatment.

Conclusions: We observed potentiation of the antihyperalgesic effect when milnacipran and tramadol were administered in combination in an animal model of fibromyalgia. Further research is required to determine the efficacy of various combination treatments in fibromyalgia in humans. (Korean J Intern Med 2009;24:139-142)

Keywords: Fibromyalgia; Pain; Acidic saline animal model; Tramadol; Milnacipran

INTRODUCTION

The acidic saline animal model of pain is thought to mimic human chronic pain syndromes such as fibromyalgia (FM). In this model, repeated intramuscular (IM) injections of acidic saline produce widespread hyperalgesia that persists without evidence of significant peripheral tissue damage or inflammation, and is believed to be centrally maintained [1]. IM acid injections alter the basal pattern of brain activation in rats [2]. The overwhelming reduction of regional cerebral blood flow (rCBF) in multiple brain structures following acid injections is consistent with reports of decreased rCBF in unstimulated patients with FM [3,4].

Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor approved for the treatment of depression in Europe and Asia, but it is currently unavailable in the US [5]. The results of a 12-week, randomized, placebo-controlled, dose-finding trial for milnacipran have been reported; 25-200 mg/day of milnacipran or placebo was given as a daily or twice-daily regimen during the first 4 weeks followed by 8 weeks at a stable dose [6]. Most FM patients titrated to the highest dose of 200 mg/day whether they were dosed once or twice daily. A significantly higher percentage of patients receiving milnacipran twice daily (37%) than placebo (14%) reported a reduction in weekly
average pain scores.

Data from imaging studies are beginning to explain clinical observations that opioid analgesics may be less effective or require higher dosing in patients with FM because of the reduced availability of opioid binding sites [7]. Many studies have shown that compounds known to block monoamine uptake, such as tricyclic antidepressants, potentiate the antinoceptive effects of opioids [8,9]. Tramadol proved useful in patients with FM in a randomized, placebo-controlled study [10].

Data regarding the efficacy of pharmacologic combination treatment for FM are very limited. To our knowledge, no study has examined pharmacologic combination treatment in an acidic saline pain model. To provide a basis for pharmacologic combination treatment for human FM, we studied the efficacy of milnacipran in conjunction with tramadol for hyperalgesia in an acidic saline animal model of pain.

METHODS

All experiments were approved by the Animal Care and Use Committee at Dongguk University and were in accordance with the guidelines of the International Association for the Study of Pain.

Twenty male Sprague-Dawley rats weighing 250-320 g were used in these experiments. The rats were maintained on a 12-h dark/light cycle with ad libitum access to standard rat chow and water, and then brought to the behavioral testing room an hour before testing for acclimatization. Behavioral tests were usually performed between 10:00 and 15:00. The left gastrocnemius muscle was injected with 100 µL of saline at pH 4.0 under brief isoflurane (2%) anesthesia on days 0 and 5.

Rats with acidic saline injection were separated into four study subgroups according to intraperitoneal injection regimen (group 1: milnacipran 60 mg/kg alone, group 2: milnacipran 40 mg/kg + tramadol 20 mg/kg, group 3: milnacipran 40 mg/kg + tramadol 40 mg/kg, group 4: saline). After measurement of the control pre-drug pain thresholds, rats were injected intraperitoneally with either of the following regimens; saline, milnacipran 60 mg/kg alone, and milnacipran 40 mg/kg in combination with tramadol 20 or 40 mg/kg. When milnacipran and tramadol were administered in combination, each agent was injected to the different regions of abdomen to prevent any possible incompatibility. Paw withdrawal thresholds to paw pressure were again measured 30 min, 120 min, and 5 days after injection. Milnacipran was a generous gift of Bukwang Pharma (Republic of Korea). Tramadol was also a generous gift of Janssen Korea Ltd. (Republic of Korea).

Ipsilateral and contralateral paw withdrawal responses were measured in response to mechanical stimuli on days 0 (baseline), 7, and 12. The tests were performed by an experimenter blinded to the treatment groups. Nociceptive thresholds, expressed in grams (g), were measured using a Dynamic Plantar Aesthesiometer (Ugo Basile, Italy) by applying increasing pressure to the right or left hind paw until the rat withdrew the paw. A maximal cut-off value of 50 g was used to prevent tissue damage.

The threshold was tested five times for each time point and the mean values were used in the analysis. One-way analysis of variance (ANOVA) followed by post hoc analysis for multiple comparisons were used to evaluate the differences between groups for each time point.

RESULTS

Compared to baseline (day 0), acid injections produced mechanical hyper-responsiveness on day 7 (pre-drug administration, p<0.05, Fig. 1 and 2). However, when milnacipran and tramadol were administered in combination via intraperitoneal injection, a potent antihyperalgesic effect was observed in the injected paw (p<0.001, Fig. 1). A similar antihyperalgesic effect was also observed in the contralateral paw when the two drugs
**DISCUSSION**

In the present study, unilateral IM injections of acidic saline produced bilateral mechanical hyperresponsiveness in Sprague-Dawley rats. In this model, a potent antihyperalgesic effect was observed when milnacipran (40 mg/kg) was combined with tramadol at a dose of 20 or 40 mg/kg. An increase in the pain threshold was observed not only in the paws on the injected side, but also in paws on the non-injected side of rats with hyperalgesia.

The affinity of antidepressants for opioid receptors is low [11]; therefore agonist-like effects of antidepressants on opioid receptors are unlikely [12]. Apart from a direct mechanism by which opioid receptors may be engaged by milnacipran, an indirect pathway may be involved in the observed increase in pain threshold in this study, perhaps via inhibition of the release of endogenous opioid peptides [13]. Several animal studies showed an increase in central nervous system (CNS) opioid peptide levels or immuno-reactivity after antidepressant treatment [14,15]. However, the mechanism by which antidepressants may increase the release of opioid peptides is yet to be identified. The results of previous studies, as well as those of the present study, indicate that further investigation is necessary to obtain more detailed information regarding the interaction of milnacipran and other non-tricyclic antidepressants with opioidergic receptors.

Although there is no established experimental animal model for FM, the acidic saline animal model of pain has been suggested to mimic FM [1]. Hyperalgesia is thought to result from changes occurring in multiple regions of the CNS, a massive integrated neural network [16,17]. Thus, the pain modulation system of the CNS should be investigated more widely. Although electrophysiological techniques are useful to investigate the pain modulation system, the identification of molecules that function in the system remains difficult. Kim et al. [18] reported that, compared to control animals, acid-injected rats showed increased expression of several pain-associated molecules in specific structures of the CNS. In addition, unilateral IM injections of acidic saline altered the basal pattern of activation in multiple CNS structures [2]. These data support the validity of the acidic saline assay as a model of FM, and provide a foundation for future analyses of the contribution of specific brain structures and cellular mechanisms to the development and maintenance of central pain syndromes.

Pregabalin has been shown to be efficacious in other pain conditions, including postoperative pain and FM. Specifically, in people with FM, pregabalin (450 mg/day) reduced pain, improved sleep, and increased quality of life [19]. More recently, it was reported that pregabalin reduced muscle and cutaneous hyperalgesia in an acidic saline model of rats [20]. Data regarding the effect of pharmacologic combination treatment in patients with FM are limited, and no study regarding pharmacologic combination treatment in an acidic saline model has been published to date. In this study, we demonstrate that a combined treatment regimen consisting of milnacipran and reduced-dosage tramadol provides adequate additive or supra-additive therapeutic effects with minimal adverse effects. Efforts to define optimal drug combinations for the relief of FM are continuing, and studies of other drugs in combination with antidepressants are potentially valuable. Therefore, further research is required to determine the efficacy of these combinations in patients with FM.

In conclusion, we demonstrated that the antihyperalgesic effect of milnacipran was potentiated when administered in combination (p=0.012, Fig. 2). However, these antihyperalgesic effects were observed only at 30 min after the combination treatments.

An additional increase in the pain threshold of the contralateral paw was observed at 30 min after treatment when 40 mg/kg of tramadol was combined with milnacipran 40 mg/kg (Fig. 2). However, this increase was not statistically significant.

**Figure 2.** Effect of the combined use of tramadol and milnacipran on the pain threshold in the contralateral paw of the rats (n=20). A potent antihyperalgesic effect was observed when the two drugs were used in combination. This was only observed at 30 min of the combination treatment. Milnacipran and tramadol were administered simultaneously to the different regions of abdomen. PD, pre-drug; gp, group; min, minutes; hrs, hours. *p=0.012
in combination with tramadol in an animal model of FM. Further research is required to determine the efficacy of various combination treatments in FM in humans.

REFERENCES

1. Sluka KA, Kalra A, Moore SA. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 2001;24:37–46.
2. Harte SE, Kim SH, Clauw DJ, Morrow TJ. Altered regional cerebral blood flow at rest in an animal model of fibromyalgia [Abstract]. Arthritis Rheum 2007;56:S9.
3. Kwiatek R, Barnden L, Tedman R, et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 2000;43:2823–2833.
4. Mountz JM, Bradley LA, Modell JG, et al. Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995;38:926–938.
5. Arnold LM. Biology and therapy of fibromyalgia: new therapies in fibromyalgia. Arthritis Res Ther 2006;8:212.
6. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975–1985.
7. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 2007;27:10000–10006.
8. Gatch MB, Negus SS, Mello NK. Antinoceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu opioid agonists in rhesus monkeys. Psychopharmacology 1998;135:99–106.
9. Sierralta F, Pinardi G, Mendez M, Miranda HF. Interaction of opioids with antidepessant-induced antinoceception. Psychopharmacology 1995;122:374–378.
10. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537–545.
11. Isenberg KE, Cicero TJ. Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds. Eur J Pharmacol 1984;103:57–63.
12. Marchand F, Ardil D, Chapuy E, Alloui A, Jourdan D, Eschalier A. Evidence for an involvement of supraspinal δ-and spinal µ-opioid receptors in the antihyperalgesic effect of chronically administered clomipramine in mononeuropathic rats. J Pharmacol Exp Ther 2003;307:268–274.
13. Gray AM, Spencer PS, Sewell RD. The involvement of the opioidergic system in the antinoceptive mechanism of action of antidepressant compounds. Br J Pharmacol 1998;124:669–674.
14. Dziedzicka-Wasylenwska M, Rogoz Z. The effect of prolonged treatment with imipramine and electroconvulsive shock on the levels of endogenous enkephalins in the nucleus accumbens and the ventral tegmentum of the rat. J Neural Transm Gen Sect 1995;102:221–228.
15. Sacerdote P, Brini A, Mantegazza P, Panerai AE. A role for serotonin and beta-endorphin in the analgesia induced by some tricyclic antidepressant drugs. Pharmacol Biochem Behav 1987;26:153–158.
16. Borsook D, Burstein R, Becerra L. Functional imaging of the human trigeminal system: opportunities for new insights into pain processing in health and disease. J Neurobiol 2004;61:107–125.
17. Rustioni A. Modulation of sensory input to the spinal cord by presynaptic ionotropic glutamate receptors. Arch Ital Biol 2005;143:103–112.
18. Kim SH, Lee J. Altered pain-associated molecules in the brain of an animal model of fibromyalgia-preliminary data [Abstract]. Ann Rheum Dis 2008;67:254.
19. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264–1273.
20. Yokoyama T, Maeda Y, Audette KM, Sluka KA. Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. J Pain 2007;8:422–429.